Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer

Brendan D. Curti, Walter J. Urba, Dan L. Longo, John Edward Janik, William H. Sharfman, Langdon L. Miller, Giovanni Cizza, Masanao Shimizu, Joost J. Oppenheim, W. Gregory Alvord, John W. Smith

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Previous primate and rodent studies suggested that interleukin-1α (IL-1α) caused changes in the secretion of pituitary, adrenal, thyroid, and gonadal hormones, as well as acute-phase reactants. Plasma samples were obtained after IL-1α and β treatment in cancer patients to document the changes in endocrine function suggested by the animal models. Successive groups of patients were treated at IL-1α doses of 0.01, 0.03, 0.1, 0.3, and 1.0 µg/kg, given daily as a 15-min intravenous bolus. IL-1β was given at 0.1 µg/kg by the same route and time course. After the first dose of IL-1, statistically significant elevations of a.m. and p.m. cortisol, growth hormone (GH), and prolactin (PRL) occurred. Thyroid-stimulating hormone (TSH) and C-reactive protein (CRP) were elevated by the sixth treatment day. Testosterone decreased significantly in male patients. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were more variable but decreased in most patients. The changes in cortisol, GH, PRL, TSH, CRP, FSH, LH, and testosterone resolved after treatment and did not result in clinically apparent endocrinopathies. Bolus doses of IL-1α and β cause significant changes in many endocrine laboratory parameters and influence the in vivo activities of multiple homeostatic endocrine functions in human beings.

Original languageEnglish (US)
Pages (from-to)142-148
Number of pages7
JournalJournal of Immunotherapy
Volume19
Issue number2
DOIs
StatePublished - Jan 1 1996

Fingerprint

Interleukin-1
Neoplasms
Follicle Stimulating Hormone
Thyrotropin
Luteinizing Hormone
Prolactin
C-Reactive Protein
Growth Hormone
Hydrocortisone
Testosterone
Gonadal Hormones
Pituitary Hormones
Acute-Phase Proteins
Thyroid Hormones
Primates
Rodentia
Therapeutics
Animal Models

Keywords

  • Cortisol
  • Interleukin-1
  • Pituitary hormones
  • Testosterone

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Curti, B. D., Urba, W. J., Longo, D. L., Janik, J. E., Sharfman, W. H., Miller, L. L., ... Smith, J. W. (1996). Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer. Journal of Immunotherapy, 19(2), 142-148. https://doi.org/10.1097/00002371-199603000-00007

Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer. / Curti, Brendan D.; Urba, Walter J.; Longo, Dan L.; Janik, John Edward; Sharfman, William H.; Miller, Langdon L.; Cizza, Giovanni; Shimizu, Masanao; Oppenheim, Joost J.; Gregory Alvord, W.; Smith, John W.

In: Journal of Immunotherapy, Vol. 19, No. 2, 01.01.1996, p. 142-148.

Research output: Contribution to journalArticle

Curti, BD, Urba, WJ, Longo, DL, Janik, JE, Sharfman, WH, Miller, LL, Cizza, G, Shimizu, M, Oppenheim, JJ, Gregory Alvord, W & Smith, JW 1996, 'Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer', Journal of Immunotherapy, vol. 19, no. 2, pp. 142-148. https://doi.org/10.1097/00002371-199603000-00007
Curti, Brendan D. ; Urba, Walter J. ; Longo, Dan L. ; Janik, John Edward ; Sharfman, William H. ; Miller, Langdon L. ; Cizza, Giovanni ; Shimizu, Masanao ; Oppenheim, Joost J. ; Gregory Alvord, W. ; Smith, John W. / Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer. In: Journal of Immunotherapy. 1996 ; Vol. 19, No. 2. pp. 142-148.
@article{5f663a7eede649899cb0c6bb09e81339,
title = "Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer",
abstract = "Previous primate and rodent studies suggested that interleukin-1α (IL-1α) caused changes in the secretion of pituitary, adrenal, thyroid, and gonadal hormones, as well as acute-phase reactants. Plasma samples were obtained after IL-1α and β treatment in cancer patients to document the changes in endocrine function suggested by the animal models. Successive groups of patients were treated at IL-1α doses of 0.01, 0.03, 0.1, 0.3, and 1.0 µg/kg, given daily as a 15-min intravenous bolus. IL-1β was given at 0.1 µg/kg by the same route and time course. After the first dose of IL-1, statistically significant elevations of a.m. and p.m. cortisol, growth hormone (GH), and prolactin (PRL) occurred. Thyroid-stimulating hormone (TSH) and C-reactive protein (CRP) were elevated by the sixth treatment day. Testosterone decreased significantly in male patients. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were more variable but decreased in most patients. The changes in cortisol, GH, PRL, TSH, CRP, FSH, LH, and testosterone resolved after treatment and did not result in clinically apparent endocrinopathies. Bolus doses of IL-1α and β cause significant changes in many endocrine laboratory parameters and influence the in vivo activities of multiple homeostatic endocrine functions in human beings.",
keywords = "Cortisol, Interleukin-1, Pituitary hormones, Testosterone",
author = "Curti, {Brendan D.} and Urba, {Walter J.} and Longo, {Dan L.} and Janik, {John Edward} and Sharfman, {William H.} and Miller, {Langdon L.} and Giovanni Cizza and Masanao Shimizu and Oppenheim, {Joost J.} and {Gregory Alvord}, W. and Smith, {John W.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1097/00002371-199603000-00007",
language = "English (US)",
volume = "19",
pages = "142--148",
journal = "Journal of Immunotherapy",
issn = "1053-8550",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Endocrine effects of IL-1α and β administered in a phase i trial to patients with advanced cancer

AU - Curti, Brendan D.

AU - Urba, Walter J.

AU - Longo, Dan L.

AU - Janik, John Edward

AU - Sharfman, William H.

AU - Miller, Langdon L.

AU - Cizza, Giovanni

AU - Shimizu, Masanao

AU - Oppenheim, Joost J.

AU - Gregory Alvord, W.

AU - Smith, John W.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Previous primate and rodent studies suggested that interleukin-1α (IL-1α) caused changes in the secretion of pituitary, adrenal, thyroid, and gonadal hormones, as well as acute-phase reactants. Plasma samples were obtained after IL-1α and β treatment in cancer patients to document the changes in endocrine function suggested by the animal models. Successive groups of patients were treated at IL-1α doses of 0.01, 0.03, 0.1, 0.3, and 1.0 µg/kg, given daily as a 15-min intravenous bolus. IL-1β was given at 0.1 µg/kg by the same route and time course. After the first dose of IL-1, statistically significant elevations of a.m. and p.m. cortisol, growth hormone (GH), and prolactin (PRL) occurred. Thyroid-stimulating hormone (TSH) and C-reactive protein (CRP) were elevated by the sixth treatment day. Testosterone decreased significantly in male patients. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were more variable but decreased in most patients. The changes in cortisol, GH, PRL, TSH, CRP, FSH, LH, and testosterone resolved after treatment and did not result in clinically apparent endocrinopathies. Bolus doses of IL-1α and β cause significant changes in many endocrine laboratory parameters and influence the in vivo activities of multiple homeostatic endocrine functions in human beings.

AB - Previous primate and rodent studies suggested that interleukin-1α (IL-1α) caused changes in the secretion of pituitary, adrenal, thyroid, and gonadal hormones, as well as acute-phase reactants. Plasma samples were obtained after IL-1α and β treatment in cancer patients to document the changes in endocrine function suggested by the animal models. Successive groups of patients were treated at IL-1α doses of 0.01, 0.03, 0.1, 0.3, and 1.0 µg/kg, given daily as a 15-min intravenous bolus. IL-1β was given at 0.1 µg/kg by the same route and time course. After the first dose of IL-1, statistically significant elevations of a.m. and p.m. cortisol, growth hormone (GH), and prolactin (PRL) occurred. Thyroid-stimulating hormone (TSH) and C-reactive protein (CRP) were elevated by the sixth treatment day. Testosterone decreased significantly in male patients. Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were more variable but decreased in most patients. The changes in cortisol, GH, PRL, TSH, CRP, FSH, LH, and testosterone resolved after treatment and did not result in clinically apparent endocrinopathies. Bolus doses of IL-1α and β cause significant changes in many endocrine laboratory parameters and influence the in vivo activities of multiple homeostatic endocrine functions in human beings.

KW - Cortisol

KW - Interleukin-1

KW - Pituitary hormones

KW - Testosterone

UR - http://www.scopus.com/inward/record.url?scp=9244232262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9244232262&partnerID=8YFLogxK

U2 - 10.1097/00002371-199603000-00007

DO - 10.1097/00002371-199603000-00007

M3 - Article

VL - 19

SP - 142

EP - 148

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1053-8550

IS - 2

ER -